small molecule

ZEPZELCA

LURBINECTEDIN

Loss of exclusivityMay 2040latest FDA-listed patent expiry

CompanyJAZZ PHARMACEUTICALS IRELAND LTD

Drug detail

Brand name	ZEPZELCA
Active ingredient	LURBINECTEDIN
Strength	4MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	June 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12324806	May 2040	use U-4212
12433890	May 2040	use U-4305
12440490	May 2040	use U-4252
7763615	December 2029	substance, product

Regulatory exclusivity

Code	Expires
I-977	October 2028
ODE-304	June 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from JAZZ PHARMACEUTICALS IRELAND LTD